A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs PF 5230907 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 15 Dec 2017 Planned End Date changed from 18 Jun 2018 to 22 Jan 2018.
- 15 Dec 2017 Planned primary completion date changed from 18 Jun 2018 to 22 Jan 2018.